Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

PCSA
Processa Pharmaceuticals, Inc. Common
stock NASDAQ

At Close
May 23, 2025 3:59:44 PM EDT
0.2400USD-2.219%(-0.0054)10,095,381
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 23, 2025 9:23:30 AM EDT
0.2470USD+1.479%(+0.0036)19,309
After-hours
May 23, 2025 4:56:30 PM EDT
0.2401USD+0.882%(+0.0021)310,003
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:15AM EST  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patients survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young.   GlobeNewswire Inc
Nov 11, 2021
04:31PM EST  Processa Pharmaceuticals Q3 EPS $(0.19) Misses $(0.18) Estimate   Benzinga
04:05PM EST  Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022   GlobeNewswire Inc
03:55AM EST  Earnings Scheduled For November 11, 2021   Benzinga
Nov 4, 2021
08:34AM EDT  Processa Pharmaceuticals Announces Its Next Generation Capecitabine Inhibited DPD Activity 24-48 Hours After PCS6422 Administration; Co. Plans To Modify Phase 1b Trial   Benzinga
08:15AM EDT  Processa Pharmaceuticals Announces Next Generation Capecitabine   GlobeNewswire Inc
Oct 26, 2021
08:30AM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021.   GlobeNewswire Inc
Oct 12, 2021
08:34AM EDT  Processa Pharma Reports Was Cleared By FDA To Proceed With Phase 2a Trial For Treatment Of Gastroparesis   Benzinga
08:32AM EDT  Processa Pharmaceuticals Cleared By FDA To Proceed With Phase 2a Trial For Gastroparesis   RTTNews
08:30AM EDT  Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a   GlobeNewswire Inc
Sep 16, 2021
11:05AM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in upcoming investor conferences:   GlobeNewswire Inc
Aug 23, 2021
04:00PM EDT  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the World Orphan Drug Congress USA 2022 Conference, to be held from August 25-27, 2022.   GlobeNewswire Inc
Aug 12, 2021
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 6, 2021
08:30AM EDT  Processa Pharmaceuticals Schedules Conference Call to Discuss   GlobeNewswire Inc
Aug 4, 2021
09:21AM EDT  Processa Earlier Announced First Patient Dosed In PCS6422 Study In Gastrointestinal Cancer   Benzinga
08:41AM EDT  Processa Doses First Patient In PCS6422 Study In Gastrointestinal Cancer   RTTNews
08:30AM EDT  Processas Phase 1bopen label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for fluoropyrimidine monotherapy.   GlobeNewswire Inc
Aug 3, 2021
03:57PM EDT  Processa Pharmaceuticals shares were trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $20 price target.   Benzinga
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021   Benzinga
04:50AM EDT  Oppenheimer Initiates Coverage On Processa Pharmaceuticals with Outperform Rating, Announces Price Target of $20   Benzinga
Jul 6, 2021
08:15AM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Processas Chief Executive Officer, Dr. David Young.   GlobeNewswire Inc
Jun 17, 2021
01:55PM EDT  Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent   Benzinga
09:20AM EDT  Processa Pharmaceuticals Says Enters Into Licensing Agreement With Ocuphire Pharma For Development Of RX-3117   Benzinga
09:15AM EDT  PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH   GlobeNewswire Inc
Jun 8, 2021
09:16AM EDT  Processa Set To Join Russell Microcap Index   Benzinga
Jun 7, 2021
04:05PM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will present at:   GlobeNewswire Inc
May 26, 2021
09:15AM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:   GlobeNewswire Inc
May 20, 2021
04:07PM EDT  Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica   Benzinga
04:05PM EDT  ~~W0:Processas trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica.Detailed information on the trial can be located on clinicaltrials.govNCT#:04800562.~~W0:   GlobeNewswire Inc
May 18, 2021
04:05PM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced today that management will participate in two upcoming investor conferences:   GlobeNewswire Inc
May 13, 2021
05:30PM EDT  Processa Pharmaceuticals Q1 EPS $(0.14) Misses $(0.10) Estimate   Benzinga
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 7, 2021
08:30AM EDT  Processa Pharmaceuticals Schedules Conference Call to Discuss   GlobeNewswire Inc
Apr 8, 2021
09:54AM EDT  Processa Pharmaceuticals Shares See Volume; Traders Circulate Disruptive Tech Research Link With 'Strong Buy' On Co   Benzinga
Mar 25, 2021
04:06PM EDT  Clinical drug pipeline is funded and targeting major milestones in 2021   GlobeNewswire Inc
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
04:03AM EDT  Earnings Scheduled For March 25, 2021   Benzinga
Mar 22, 2021
09:15AM EDT  Processa Pharmaceuticals Schedules Conference Call to Discuss   GlobeNewswire Inc
Mar 17, 2021
09:19AM EDT  Processa Announces Sites Selected For Phase 2B Clinical Trial To Treat Patients With Ulcerated Necrobiosis Lipoidica   Benzinga
09:15AM EDT  Processa Announces Sites Selected for Phase 2B Clinical Trial to   GlobeNewswire Inc
Mar 2, 2021
09:15AM EST  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accredited investors of $10.2 million. The Company sold 1,321,132 shares of the common stock at a purchase price of $7.75 per share for $10.2 million in the private placement. The Company received net proceeds of $9.9 million.   GlobeNewswire Inc
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 18, 2021
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 17, 2021
02:31PM EST  Mid-Afternoon Market Update: Dow Turns Positive; Luokung Technology Shares Plunge   Benzinga
12:11PM EST  Mid-Day Market Update: Gold Falls Over 1%; Comstock Mining Shares Spike Higher   Benzinga
08:11AM EST  Processa Pharmaceuticals Executes Securities Purchase Agreement To Raise Gross Proceeds Of $10.2M From Sale Of 1,321,132 Shares At $7.75/Share   Benzinga
08:00AM EST  Processa Pharmaceuticals Announces $10.2 Million Strategic Financing   GlobeNewswire Inc
Jan 11, 2021
10:50AM EST  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.   GlobeNewswire Inc
Dec 21, 2020
02:24PM EST  Processa Pharmaceuticals Reports FDA Approves OTC Coronavirus Home-Sample Collection Kit   Benzinga
Nov 16, 2020
12:48PM EST  via InvestorWire Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:   GlobeNewswire Inc
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 3, 2020
09:22AM EST  Processa Pharmaceuticals To Discuss Q3 Results, Provide Drug Development Update On Nov. 12 At 5:30 p.m. EST; To Discuss PCS6422 Combined With Fluoropyrimidines; PCS499 To Treat Ulcerated Necrobiosis Lipoidica   Benzinga
09:20AM EST  Processa Pharmaceuticals Schedules Conference Call to Discuss   GlobeNewswire Inc
Oct 28, 2020
12:39PM EDT  Craig-Hallum Initiates Coverage On Processa Pharmaceuticals with Buy Rating, Announces Price Target of $12   Benzinga
Oct 13, 2020
10:48AM EDT  Processa Pharmaceuticals Appoints Michael Floyd As COO   RTTNews
10:13AM EDT  David Young Reports In 13D Filing A 14.2% Stake In Processa Pharmaceuticals   Benzinga
09:35AM EDT  Process Pharmaceuticals Announces Appointment Of Michael Floyd As COO   Benzinga
09:30AM EDT  Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (Processa or the Company), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, is pleased to announce the appointment of Michael Floyd as the Companys Chief Operating Officer.   GlobeNewswire Inc
Oct 6, 2020
04:05PM EDT  Processa Pharmaceuticals Closes $19.2 Million Public Offering   GlobeNewswire Inc
Oct 2, 2020
06:02AM EDT  Processa Pharma Prices IPO Of 4.8M Shares At $4/Share   Benzinga
06:00AM EDT  Processa Pharmaceuticals Announces Pricing of $19.2 Million Public   GlobeNewswire Inc
Aug 27, 2020
09:30AM EDT  PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT   GlobeNewswire Inc
Aug 20, 2020
09:30AM EDT  Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean based company, to license in YH12852. YH12852 is a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC